Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
S. L. Leibel, R. N. McVicar, R. Murad, E. M. Kwong, A. E. Clark, A. Alvarado, B. A. Grimmig, R. Nuryyev, R. E. Young, J. C. Lee, W. Peng, Y. P. Zhu, E. Griffis, C. J. Nowell, B. James, , E. Y. Snyder
This study shows that surfactant proteins mediate an intrinsic inflammatory response in the lung to defend against SARS-CoV-2 infection.
bioRxiv · Jan 26, 2023 · PreprintImmunology
G. Almanza, V. Kouznetsova, A. E. Clark, E. Olmedillas, A. Castro, I. F. Tsigelny, Y. Wu, G. F. Gao, E. Ollmann Saphire, A. F. Carlin, M. Zanetti
This study shows that structure-selected RBM immunogens induce polyclonal memory responses that neutralize SARS-CoV-2 variants of concern.
PLOS Pathogens · Jul 21, 2022Peer-reviewedImmunology
R. Li, M. Mor, B. Ma, A. E. Clark, J. Alter, M. Werbner, J. Lee, S. L. Leibel, A. F. Carlin, M. Dassau, M. Gal-Tanamy, B. A. Croker, Y. Xiang, N. T. Freund
This study evaluates the neutralizing activity of nine anti-SARS-CoV-2 monoclonal antibodies against variants of concern and reveals their structural mechanisms of action.
bioRxiv · Apr 3, 2022Immunology
R. T. Schooley, A. F. Carlin, J. R. Beadle, N. Valiaeva, X.-Q. Zhang, A. E. Clark, R. E. McMillian, S. L. Leibel, R. N. McVicar, J. Xie, A. F. Garretson, V. I. Smith, J. A. Murphy, K. Y. Hostetler
This paper develops orally bioavailable lipid prodrugs of Remdesivir that show submicromolar anti-SARS-CoV-2 activity and therapeutic plasma levels in Syrian hamsters.
Antimicrobial Agents and Chemotherapy · Sep 17, 2021Peer-reviewedMicrobiology
R. A. Salido, V. J. Cantu, A. E. Clark, S. L. Leibel, A. Foroughishafiei, A. Saha, A. Hakim, A. Nouri, A. L. Lastrella, A. Castro-Martinez, A. Plascencia, B. Kapadia, B. Xia, C. Ruiz, C. Marotz, , R. Knight
This study compares RT-qPCR signal intensity and persistence of heat-inactivated and infectious SARS-CoV-2 on different surfaces, showing similar decay patterns and enabling simplified environmental monitoring protocols.
bioRxiv · Jul 16, 2021 · PreprintMicrobiology
T. M. Clausen, D. R. Sandoval, C. B. Spliid, J. Pihl, C. D. Painter, B. E. Thacker, C. A. Glass, A. Narayanan, S. A. Majowicz, Y. Zhang, J. L. Torres, G. J. Golden, R. Porell, A. F. Garretson, L. Laubach, , J. D. Esko
This study shows SARS-CoV-2 spike protein binds to heparan sulfate and ACE2 on cells codependently, forming a complex that facilitates infection, suggesting potential therapeutic targets.
Cell · Nov 1, 2020Peer-reviewedMicrobiology
D. Mellott, C.-T. Tseng, A. Drelich, P. Fajtova, B. C. Chenna, D. Kostomiris, J. C. Hsu, J. Zhu, Z. Taylor, V. Tat, A. Katzfuss, L. Li, M. A. Giardini, D. Skinner, K. Hirata, , J. H. McKerrow
This paper shows that K777, a cysteine protease inhibitor, blocks SARS-CoV-2 infection by inhibiting host cathepsin L, which is required for spike protein processing, with nanomolar efficacy in several cell lines.
bioRxiv · Oct 23, 2020 · PreprintBiochemistry
M. Mor, M. Werbner, J. Alter, M. Safra, E. Chomsky, S. Hada-Neeman, K. Polonsky, C. Nowell, A. Clark, A. Roitburd-Berman, N. Ben-Shalom, M. Navon, D. Rafael, H. Sharim, E. Kiner, , N. Freund
This study identifies multi-clonal neutralizing antibodies against SARS-CoV-2 in severe COVID-19 patients and shows their potential for combination therapy.
bioRxiv · Oct 6, 2020Immunology